New research in the Journal of Substance Use & Addiction Treatment highlights the growing potential of smart harm reduction vending machines as a low-barrier strategy for improving overdose prevention, public health access, and community-based support services. The study evaluated two “smart” vending machines placed in community settings and found that this model can help expand access to naloxone, health supplies, and other harm reduction resources while also connecting users to local services through touchscreen technology and anonymous data collection.

A new federal policy shift is intensifying debate around harm reduction, overdose prevention, and the nation’s response to the fentanyl crisis. The Trump administration, through updated guidance from the Substance Abuse and Mental Health Services Administration, has ended the use of certain federal grant funds for fentanyl test strips and other substance test kits distributed for individual use, reversing prior federal support for these tools.

Purdue Pharma, the maker of OxyContin, has officially ceased operations as part of its long-running bankruptcy resolution, marking a major milestone in the ongoing response to the opioid epidemic. The company is being replaced by Knoa Pharma, a new public benefit corporation that will operate under independent oversight and direct its net profits toward efforts to address opioid addiction, prevention, treatment, and recovery.

President Donald Trump’s recent executive order easing some federal restrictions on psychedelic substances is drawing national attention to the growing role of psychedelic research in mental health treatment, addiction care, and veteran health. The order is intended to accelerate research into psychedelic therapies and support faster review of certain investigational treatments already moving through the FDA process.

A major change in federal cannabis policy could reshape conversations across healthcare, pharmacy, addiction medicine, and public policy. The U.S. Department of Justice has moved state-licensed medical marijuana from Schedule I to Schedule III, signaling a historic shift in how medical cannabis is regulated at the federal level. While the order does not legalize marijuana under federal law, it does reduce regulatory barriers, expand opportunities for cannabis research, and allow licensed medical marijuana businesses to deduct standard business expenses on federal taxes.

A recent study in the Journal of Addiction Medicine examines how individuals who use drugs—particularly nonprescribed stimulants—perceive opioid overdose risk and the barriers and facilitators to prevention strategies such as naloxone distribution. The findings highlight a critical disconnect between actual overdose risk and personal risk perception, a factor that continues to drive preventable deaths in the U.S. opioid crisis.

(March 12, 2026) A new synthetic opioid known as N-propionitrile chlorphine—commonly referred to as cychlorphine—has been linked to at least 16 overdose deaths in East Tennessee over the past several months, according to preliminary toxicology reports from the Knox County Regional Forensic Center.

(February 19, 2026) Recent wastewater analysis in Nantucket, Massachusetts has revealed cocaine concentrations up to three times the U.S. national average, underscoring the potential of wastewater surveillance as a tool for tracking community drug trends. Testing conducted since summer 2025 at the town’s Surfside treatment facility found peak cocaine readings of nearly 2,950 nanograms per liter, significantly higher than typical national wastewater benchmarks of around 900–1,000 ng/L.

(February 20, 2026) The U.S. Department of Health and Human Services’ Administration for Children and Families (ACF) has announced that three FDA-approved Medications for Opioid Use Disorder (MOUD) — buprenorphine, methadone, and naltrexone — are now eligible for funding under Title IV-E Prevention Services.

(February 3, 2026) The U.S. Department of Health and Human Services (HHS), under Secretary Robert F. Kennedy Jr., unveiled a series of federal actions aimed at addressing addiction, homelessness and related behavioral health challenges. These moves build on a recent executive order from President Donald Trump focused on expanding national efforts to combat substance use disorders.

(January 30, 2026) The White House has issued an Executive Order establishing the Great American Recovery Initiative, a federal effort intended to coordinate and strengthen the national response to addiction and substance use disorder. The order cites an estimated 48.4 million Americans affected by addiction and calls for improved alignment across federal programs focused on prevention, treatment, and recovery.